Massive
Science

Stories
Follow
Write for us
Shop
About

Close

Sign up
Sign in

Massive
Science Menu Search Account

Sections

Front Page
Credits
Bibliography

Chapter 1

The dawn of psychedelics
Chapter 2

Trip to the doctor
- How do psychedelics affect the brain?
- What research and treatments are on the horizon?
Chapter 3

Mind-altering illnesses
Chapter 4

The reality of the situtation

Opening Our Minds

Discussion

Bibliography

Akers, B. P., Ruiz, J. F., Piper, A., & Ruck, C. A. P. (2011). A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?1. Economic Botany, 65(2), 121–128. https://doi.org/10.1007/s12231-011-9152-5
Alper, K. R. (2001). Chapter 1 Ibogaine: A review. The Alkaloids: Chemistry and Biology, 1–38. https://doi.org/10.1016/s0099-9598(01)56005-8
Andrade, C., & Sathyanarayana Rao, T. (2017). A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry. Indian Journal of Psychiatry, 59(3), 259. https://doi.org/10.4103/psychiatry.indianjpsychiatry_345_17
Badcock, J. C., Dehon, H., & Larøi, F. (2017). Hallucinations in Healthy Older Adults: An Overview of the Literature and Perspectives for Future Research. Frontiers in Psychology, 8. https://doi.org/10.3389/fpsyg.2017.01134
Ban, T. A. (2007). Fifty years chlorpromazine: a historical perspective. Neuropsychiatric Disease and Treatment, 3(4), 495–500.
Bar, K.-J., & Ebert, A. (2010). Emil Kraepelin: A pioneer of scientific understanding of psychiatry and psychopharmacology. Indian Journal of Psychiatry, 52(2), 191. https://doi.org/10.4103/0019-5545.64591
Baumeister, D., Sedgwick, O., Howes, O., & Peters, E. (2017). Auditory verbal hallucinations and continuum models of psychosis: A systematic review of the healthy voice-hearer literature. Clinical Psychology Review, 51, 125–141. https://doi.org/10.1016/j.cpr.2016.10.010
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. https://doi.org/10.1177/0269881114565144
Caldieraro, M. A., Dufour, S., Sylvia, L. G., Gao, K., Ketter, T. A., Bobo, W. V., … Nierenberg, A. A. (2018). Treatment outcomes of acute bipolar depressive episode with psychosis. Depression and Anxiety, 35(5), 402–410. https://doi.org/10.1002/da.22716
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., … Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/10.1016/s2215-0366(16)30065-7
Carod-Artal, F. J. (2015). Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurología (English Edition), 30(1), 42–49. https://doi.org/10.1016/j.nrleng.2011.07.010
Chaudhury, S. (2010). Hallucinations: Clinical aspects and management. Industrial Psychiatry Journal, 19(1), 5. https://doi.org/10.4103/0972-6748.77625
Cohen, S. (1962). Complications Associated with Lysergic Acid Diethylamide (LSD-25). JAMA: The Journal of the American Medical Association, 181(2), 161. https://doi.org/10.1001/jama.1962.03050280091013b
Connors, M. H., Robidoux, S., Langdon, R., & Coltheart, M. (2016). Beliefs about hearing voices. Consciousness and Cognition, 43, 89–101. https://doi.org/10.1016/j.concog.2016.05.001
Dargham A, Abi & Gil, Roberto & Krystal, J & Baldwin, Rm & Bowers, M & Dyck Ch, Van & Charney, Ds & Innis, Rb & Laruelle, Marc. (1998). Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry. 155. https://doi.org/10.1176/ajp.155.6.761.
Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016). Lysergic acid diethylamide: a drug of “use”? Therapeutic Advances in Psychopharmacology, 6(3), 214–228. https://doi.org/10.1177/2045125316640440
DeRosse, P., & Karlsgodt, K. H. (2015). Examining the Psychosis Continuum. Current Behavioral Neuroscience Reports, 2(2), 80–89. https://doi.org/10.1007/s40473-015-0040-7
Dos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016). The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. Journal of Psychopharmacology, 30(12), 1230–1247. https://doi.org/10.1177/0269881116652578
Dutta, V. (2012). Repression of death consciousness and the psychedelic trip. Journal of Cancer Research and Therapeutics, 8(3), 336. https://doi.org/10.4103/0973-1482.103509
El-Seedi, H. R., Smet, P. A. G. M. D., Beck, O., Possnert, G., & Bruhn, J. G. (2005). Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. Journal of Ethnopharmacology, 101(1-3), 238–242. https://doi.org/10.1016/j.jep.2005.04.022
Everaert, J., Koster, E. H. W., & Derakshan, N. (2012). The combined cognitive bias hypothesis in depression. Clinical Psychology Review, 32(5), 413–424. https://doi.org/10.1016/j.cpr.2012.04.003
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2008). The behavioral pharmacology of hallucinogens. Biochemical Pharmacology, 75(1), 17–33. https://doi.org/10.1016/j.bcp.2007.07.018
Friston, K. (2009). The free-energy principle: a rough guide to the brain? Trends in Cognitive Sciences, 13(7), 293–301. https://doi.org/10.1016/j.tics.2009.04.005
GRAHAM, J. R. (1938). MECHANISM OF MIGRAINE HEADACHE AND ACTION OF ERGOTAMINE TARTRATE. Archives of Neurology And Psychiatry, 39(4), 737. https://doi.org/10.1001/archneurpsyc.1938.02270040093005
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., … Sealfon, S. C. (2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 452(7183), 93–97. https://doi.org/10.1038/nature06612
Green, J. P., Laurence, J.-R., & Lynn, S. J. (2014). Hypnosis and psychotherapy: From Mesmer to mindfulness. Psychology of Consciousness: Theory, Research, and Practice, 1(2), 199–212. https://doi.org/10.1037/cns0000015
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., … Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513
Grimby, A. (1993). Bereavement among elderly people: grief reactions, post-bereavement hallucinations and quality of life. Acta Psychiatrica Scandinavica, 87(1), 72–80. https://doi.org/10.1111/j.1600-0447.1993.tb03332.x
Gründer, G., Hippius, H., & Carlsson, A. (2009). The “atypicality” of antipsychotics: a concept re-examined and re-defined. Nature Reviews Drug Discovery, 8(3), 197–202. https://doi.org/10.1038/nrd2806
Guo, X., Zhai, J., Liu, Z., Fang, M., Wang, B., Wang, C., … Zhao, J. (2010). Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia. Archives of General Psychiatry, 67(9), 895. https://doi.org/10.1001/archgenpsychiatry.2010.105
Hagenaars, M. A., van Minnen, A., & Hoogduin, K. A. L. (2010). The impact of dissociation and depression on the efficacy of prolonged exposure treatment for PTSD. Behaviour Research and Therapy, 48(1), 19–27. https://doi.org/10.1016/j.brat.2009.09.001
Hampson, C. L., Body, S., den Boon, F. S., Cheung, T. H. C., Bezzina, G., Langley, R. W., … Szabadi, E. (2010). Comparison of the effects of 2,5-dimethoxy-4-iodoamphetamine and D-amphetamine on the ability of rats to discriminate the durations and intensities of light stimuli. Behavioural Pharmacology, 21(1), 11–20. https://doi.org/10.1097/fbp.0b013e328334707a
Holmes, A. J., & Patrick, L. M. (2018). The Myth of Optimality in Clinical Neuroscience. Trends in Cognitive Sciences, 22(3), 241–257. https://doi.org/10.1016/j.tics.2017.12.006
Holmes, E. A., Ghaderi, A., Harmer, C. J., Ramchandani, P. G., Cuijpers, P., Morrison, A. P., … Craske, M. G. (2018). The Lancet Psychiatry Commission on psychological treatments research in tomorrow’s science. The Lancet Psychiatry, 5(3), 237–286. https://doi.org/10.1016/s2215-0366(17)30513-8
Horvath, A. O., Del Re, A. C., Flückiger, C., & Symonds, D. (2011). Alliance in individual psychotherapy. Psychotherapy, 48(1), 9–16. https://doi.org/10.1037/a0022186
Hudepohl, N. S., & Nasrallah, H. A. (2012). Antipsychotic drugs. Handbook of Clinical Neurology, 657–667. https://doi.org/10.1016/b978-0-444-52002-9.00039-5
JOHNS, L. C., ROSSELL, S., FRITH, C., AHMAD, F., HEMSLEY, D., KUIPERS, E., & McGUIRE, P. K. (2001). Verbal self-monitoring and auditory verbal hallucinations in patients with schizophrenia. Psychological Medicine, 31(04). https://doi.org/10.1017/s0033291701003774
Johansen, P., & Krebs, T. (2009). How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. Journal of Psychopharmacology, 23(4), 389–391. https://doi.org/10.1177/0269881109102787
Johns, L. C. (2005). Hallucinations in the general population. Current Psychiatry Reports, 7(3), 162–167. https://doi.org/10.1007/s11920-005-0049-9
Johns, L. C., Cannon, M., Singleton, N., Murray, R. M., Farrell, M., Brugha, T., … Meltzer, H. (2004). Prevalence and correlates of self-reported psychotic symptoms in the British population. British Journal of Psychiatry, 185(04), 298–305. https://doi.org/10.1192/bjp.185.4.298
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2016). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55–60. https://doi.org/10.3109/00952990.2016.1170135
Kleisiaris, C. F., Sfakianakis, C., & Papathanasiou, I. V. (2014). Health care practices in ancient Greece: The Hippocratic ideal. Journal of Medical Ethics and History of Medicine, 7, 6.
Kometer, M., Schmidt, A., Jancke, L., & Vollenweider, F. X. (2013). Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations. Journal of Neuroscience, 33(25), 10544–10551. https://doi.org/10.1523/jneurosci.3007-12.2013
Krebs, T. S., & Johansen, P.-Ø. (2013). Psychedelics and Mental Health: A Population Study. PLoS ONE, 8(8), e63972. https://doi.org/10.1371/journal.pone.0063972
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002). Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment, 23(4), 273–283. https://doi.org/10.1016/s0740-5472(02)00275-1
Lalanne, L., Nicot, C., Lang, J.-P., Bertschy, G., & Salvat, E. (2016). Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report. BMC Psychiatry, 16(1). https://doi.org/10.1186/s12888-016-1112-2
Larøi, F. (2012). How do auditory verbal hallucinations in patients differ from those in non-patients? Frontiers in Human Neuroscience, 6. https://doi.org/10.3389/fnhum.2012.00025
Larøi, F., Linden, M., & Marczewski, P. (2004). The effects of emotional salience, cognitive effort and meta-cognitive beliefs on a reality monitoring task in hallucination-prone subjects. British Journal of Clinical Psychology, 43(3), 221–233. https://doi.org/10.1348/0144665031752970
Launay, G., & Slade, P. (1981). The measurement of hallucinatory predisposition in male and female prisoners. Personality and Individual Differences, 2(3), 221–234. https://doi.org/10.1016/0191-8869(81)90027-1
Launer, J. (2005). Anna O and the “talking cure.” QJM: An International Journal of Medicine, 98(6), 465–466. https://doi.org/10.1093/qjmed/hci068
Liston, C., Chen, A. C., Zebley, B. D., Drysdale, A. T., Gordon, R., Leuchter, B., … Dubin, M. J. (2014). Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biological Psychiatry, 76(7), 517–526. https://doi.org/10.1016/j.biopsych.2014.01.023
Lonergan, A. (2017). The meaning of voices in understanding and treating psychosis: Moving towards intervention informed by collaborative formulation. Europe’s Journal of Psychology, 13(2), 352–365. https://doi.org/10.5964/ejop.v13i2.1199
López-Muñoz, F., Alamo, C., cuenca, E., Shen, W., Clervoy, P., & Rubio, G. (2005). History of the Discovery and Clinical Introduction of Chlorpromazine. Annals of Clinical Psychiatry, 17(3), 113–135. https://doi.org/10.1080/10401230591002002
Malhi, G. S., Tanious, M., Das, P., Coulston, C. M., & Berk, M. (2013). Potential Mechanisms of Action of Lithium in Bipolar Disorder. CNS Drugs, 27(2), 135–153. https://doi.org/10.1007/s40263-013-0039-0
Mashour, G. A., Walker, E. E., & Martuza, R. L. (2005). Psychosurgery: past, present, and future. Brain Research Reviews, 48(3), 409–419. https://doi.org/10.1016/j.brainresrev.2004.09.002
Mattelaer, J. J., & Jilek, W. (2007). SEXUAL MEDICINE HISTORY: Koro—The Psychological Disappearance of the Penis. The Journal of Sexual Medicine, 4(5), 1509–1515. https://doi.org/10.1111/j.1743-6109.2007.00586.x
McCarthy-Jones, S., Marriott, M., Knowles, R., Rowse, G., & Thompson, A. R. (2013). What is psychosis? A meta-synthesis of inductive qualitative studies exploring the experience of psychosis. Psychosis, 5(1), 1–16. https://doi.org/10.1080/17522439.2011.647051
McGrath, J. J., Saha, S., Al-Hamzawi, A., Alonso, J., Bromet, E. J., Bruffaerts, R., … Kessler, R. C. (2015). Psychotic Experiences in the General Population. JAMA Psychiatry, 72(7), 697. https://doi.org/10.1001/jamapsychiatry.2015.0575
Miller, G. M. (2010). The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. Journal of Neurochemistry, 116(2), 164–176. https://doi.org/10.1111/j.1471-4159.2010.07109.x
Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., … Doblin, R. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry, 5(6), 486–497. https://doi.org/10.1016/s2215-0366(18)30135-4
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., … Doblin, R. (2012). Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. Journal of Psychopharmacology, 27(1), 28–39. https://doi.org/10.1177/0269881112456611
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., & Riba, J. (2017). The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-05407-9
Moukaddam, N. J., & Hirschfeld, R. M. A. (2004). Intravenous antidepressants: A review. Depression and Anxiety, 19(1), 1–9. https://doi.org/10.1002/da.10135
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., … Mathew, S. J. (2013). Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. American Journal of Psychiatry, 170(10), 1134–1142. https://doi.org/10.1176/appi.ajp.2013.13030392
Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002
Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478
Nutt, D. J., King, L. A., & Nichols, D. E. (2013). Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience, 14(8), 577–585. https://doi.org/10.1038/nrn3530
Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752), 1558–1565. https://doi.org/10.1016/s0140-6736(10)61462-6
Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2012). A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology, 27(1), 40–52. https://doi.org/10.1177/0269881112464827
Olson, P. R., Suddeth, J. A., Peterson, P. J., & Egelhoff, C. (1985). Hallucinations of Widowhood. Journal of the American Geriatrics Society, 33(8), 543–547. https://doi.org/10.1111/j.1532-5415.1985.tb04619.x
Osoegawa, C., Gomes, J. S., Grigolon, R. B., Brietzke, E., Gadelha, A., Lacerda, A. L. T., … Trevizol, A. P. (2018). Non-invasive brain stimulation for negative symptoms in schizophrenia: An updated systematic review and meta-analysis. Schizophrenia Research. https://doi.org/10.1016/j.schres.2018.01.010
Osório, F. de L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., … Hallak, J. E. (2015). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Revista Brasileira de Psiquiatria, 37(1), 13–20. https://doi.org/10.1590/1516-4446-2014-1496
Pagnin, D., de Queiroz, V., Pini, S., & Cassano, G. B. (2008). Efficacy of ECT in Depression: A Meta-Analytic Review. FOCUS, 6(1), 155–162. https://doi.org/10.1176/foc.6.1.foc155
Pahnke, W. N. (1970). The Experimental Use of Psychedelic (LSD) Psychotherapy. JAMA: The Journal of the American Medical Association, 212(11), 1856. https://doi.org/10.1001/jama.1970.03170240060010
Pai, A., & Heining, M. (2007). Ketamine. Continuing Education in Anaesthesia Critical Care & Pain, 7(2), 59–63. https://doi.org/10.1093/bjaceaccp/mkm008
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., … de Araujo, D. B. (2015). The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network. PLOS ONE, 10(2), e0118143. https://doi.org/10.1371/journal.pone.0118143
Passie, T. (2018). The early use of MDMA (“Ecstasy”) in psychotherapy (1977–1985). Drug Science, Policy and Law, 4, 205032451876744. https://doi.org/10.1177/2050324518767442
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., … Schoepp, D. D. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine, 13(9), 1102–1107. https://doi.org/10.1038/nm1632
Petersen, C. A. (2007). A Historical Look at Psychology and the Scientist-Practitioner Model. American Behavioral Scientist, 50(6), 758–765. https://doi.org/10.1177/0002764206296453
Prue, R., & Voss, R. W. (2014). Indigenous Healing Practice: Ayahuasca. Opening a Discussion. Journal of Pastoral Care & Counseling: Advancing Theory and Professional Practice through Scholarly and Reflective Publications, 68(1), 1–13. https://doi.org/10.1177/154230501406800106
Resick, P. A., Suvak, M. K., Johnides, B. D., Mitchell, K. S., & Iverson, K. M. (2012). THE IMPACT OF DISSOCIATION ON PTSD TREATMENT WITH COGNITIVE PROCESSING THERAPY. Depression and Anxiety, 29(8), 718–730. https://doi.org/10.1002/da.21938
Rolland, B., Jardri, R., Amad, A., Thomas, P., Cottencin, O., & Bordet, R. (2014). Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom? BioMed Research International, 2014, 1–9. https://doi.org/10.1155/2014/307106
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., … Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512
Rucker, J. J. H. (2015). Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. BMJ, 350(may26 20), h2902–h2902. https://doi.org/10.1136/bmj.h2902
Saar, M. (1991). Ethnomycological data from siberia and north-east asia on the effect of Amanita muscaria. Journal of Ethnopharmacology, 31(2), 157–173. https://doi.org/10.1016/0378-8741(91)90002-u
Sackeim, H. A., Prudic, J., Devanand, D. P., Nobler, M. S., Lisanby, S. H., Peyser, S., … Clark, J. (2000). A Prospective, Randomized, Double-blind Comparison of Bilateral and Right Unilateral Electroconvulsive Therapy at Different Stimulus Intensities. Archives of General Psychiatry, 57(5), 425. https://doi.org/10.1001/archpsyc.57.5.425
Sanacora, G., Treccani, G., & Popoli, M. (2012). Towards a glutamate hypothesis of depression. Neuropharmacology, 62(1), 63–77. https://doi.org/10.1016/j.neuropharm.2011.07.036
Sandison, R. A., Spencer, A. M., & Whitelaw, J. D. A. (1954). The Therapeutic Value of Lysergic Acid Diethylamide in Mental Illness. Journal of Mental Science, 100(419), 491–507. https://doi.org/10.1192/bjp.100.419.491
Schadlu, A. P., Schadlu, R., & Shepherd, J. B. (2009). Charles Bonnet syndrome: a review. Current Opinion in Ophthalmology, 20(3), 219–222. https://doi.org/10.1097/icu.0b013e328329b643
Schaefer, J. D., Caspi, A., Belsky, D. W., Harrington, H., Houts, R., Horwood, L. J., … Moffitt, T. E. (2017). Enduring mental health: Prevalence and prediction. Journal of Abnormal Psychology, 126(2), 212–224. https://doi.org/10.1037/abn0000232
Schiff, P. L. (2006). Ergot and Its Alkaloids. American Journal of Pharmaceutical Education, 70(5), 98. https://doi.org/10.5688/aj700598
Schultes, R. E. (1969). Hallucinogens of Plant Origin. Science, 163(3864), 245–254. https://doi.org/10.1126/science.163.3864.245
Scult, M. A., Knodt, A. R., Swartz, J. R., Brigidi, B. D., & Hariri, A. R. (2016). Thinking and Feeling. Clinical Psychological Science, 5(1), 150–157. https://doi.org/10.1177/2167702616654688
Shen, W. W. (1999). A history of antipsychotic drug development. Comprehensive Psychiatry, 40(6), 407–414. https://doi.org/10.1016/s0010-440x(99)90082-2
Shepherd, M. (1994). Neurolepsis and the psychopharmacological revolution: myth and reality. History of Psychiatry, 5(17), 089–96. https://doi.org/10.1177/0957154x9400501705
Singh, A., & Kar, S. K. (2017). How Electroconvulsive Therapy Works?: Understanding the Neurobiological Mechanisms. Clinical Psychopharmacology and Neuroscience, 15(3), 210–221. https://doi.org/10.9758/cpn.2017.15.3.210
Skolnick, P., Popik, P., & Trullas, R. (2009). Glutamate-based antidepressants: 20 years on. Trends in Pharmacological Sciences, 30(11), 563–569. https://doi.org/10.1016/j.tips.2009.09.002
Smith, K. (2017). The best drug treatment for psychotic depression: Antidepressants, antipsychotics or both combined? Commentary On… Cochrane Cornea. BJPsych Advances, 23(1), 3–8. https://doi.org/10.1192/apt.23.1.3
St John Sessa, B. (2008). Are psychedelic drug treatments seeing a comeback in psychiatry? Progress in Neurology and Psychiatry, 12(8), 5–10. https://doi.org/10.1002/pnp.94
Stanghellini, G., Langer, Á. I., Ambrosini, A. andra, & Cangas, A. J. (2012). Quality of hallucinatory experiences: differences between a clinical and a non-clinical sample. World Psychiatry, 11(2), 110–113. https://doi.org/10.1016/j.wpsyc.2012.05.007
Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015). Psychotherapy for Military-Related PTSD. JAMA, 314(5), 489. https://doi.org/10.1001/jama.2015.8370
Taylor, D. J., & Pruiksma, K. E. (2014). Cognitive and behavioural therapy for insomnia (CBT-I) in psychiatric populations: A systematic review. International Review of Psychiatry, 26(2), 205–213. https://doi.org/10.3109/09540261.2014.902808
Terry, M., Steelman, K. L., Guilderson, T., Dering, P., & Rowe, M. W. (2006). Lower Pecos and Coahuila peyote: new radiocarbon dates. Journal of Archaeological Science, 33(7), 1017–1021. https://doi.org/10.1016/j.jas.2005.11.008
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., … Taipale, H. (2017). Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. JAMA Psychiatry, 74(7), 686. https://doi.org/10.1001/jamapsychiatry.2017.1322
Tylš, F., Páleníček, T., & Horáček, J. (2014). Psilocybin – Summary of knowledge and new perspectives. European Neuropsychopharmacology, 24(3), 342–356. https://doi.org/10.1016/j.euroneuro.2013.12.006
Tzeferakos, G. A., & Douzenis, A. I. (2017). Islam, mental health and law: a general overview. Annals of General Psychiatry, 16(1). https://doi.org/10.1186/s12991-017-0150-6
Van Os, J., Hanssen, M., Bijl, R. V., & Vollebergh, W. (2001). Prevalence of Psychotic Disorder and Community Level of Psychotic Symptoms. Archives of General Psychiatry, 58(7), 663. https://doi.org/10.1001/archpsyc.58.7.663
Whitfield-Gabrieli, S., & Ford, J. M. (2012). Default Mode Network Activity and Connectivity in Psychopathology. Annual Review of Clinical Psychology, 8(1), 49–76. https://doi.org/10.1146/annurev-clinpsy-032511-143049
Zhou, Y., & Danbolt, N. C. (2014). Glutamate as a neurotransmitter in the healthy brain. Journal of Neural Transmission, 121(8), 799–817. https://doi.org/10.1007/s00702-014-1180-8
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016). Ketamine: NMDA Receptors and Beyond. Journal of Neuroscience, 36(44), 11158–11164. https://doi.org/10.1523/jneurosci.1547-16.2016

Ad

Massive
Science

We're a community of scientists telling fascinating, true stories about the science that's happening now.

Facebook
Instagram
Twitter
RSS Feed

© 2017 – 2020 Massive Science Inc.